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List of abbreviations 
 
ALL  acute lymphoblastic leukemia 
B-ALL B-cell ALL 
BFM  Berlin-Frankfurt-Münster 
cDNA  complementary DNA 
DAPI  4',6-diamidino-2-phenylindole 
DNA  deoxyribonucleic acid 
ETV6  ETS variant gene (formerly TEL) 
FCM  flow cytometry 
FISH  fluorescence in situ hybridization 
FITC  fluorescein isothiocyanate 
G6PDH glucose-6-phosphate dehydrogenase 
iFISH  FISH on interphase nucleus 
IG  immunoglobulin 
IGH  immunoglobulin heavy chain 
IGK  immunoglobulin kappa light chain 
Kde  kappa deleting element 
LOH  loss of heterozygosity 
MNC  mononuclear cell 
MRD  minimal residual disease 
mRNA messenger ribonucleic acid 
pALL  pediatric ALL 
PCR  polymerase chain reaction 
RNA  ribonucleic acid 
RQ-PCR  real-time quantitative PCR 
RQ-RT-PCR  real-time quantitative reverse transcription PCR 
RT-PCR reverse transcription PCR 
RUNX1 runt-related transcription factor 1 gene (formerly AML1) 
SFM scanning fluorescence microscopy 
TCR  T-cell receptor 
TCRD  T-cell receptor delta  
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1. Introduction 
 
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy.  
The results achieved in recent decades in the treatment of pediatric ALL (pALL) speak for 
themselves, the less than 10% five-year survival rate experienced in the 1960s has risen these 
days to 85-90%. In our days the therapeutic goal is not only to improve survival, but also to 
identify subgroups of patients curable with less aggressive treatment and to define  
a risk-based therapy.  
The development of immunological and molecular techniques allowed the detection of 
residual disease below the sensitivity level of morphological methods. Minimal residual 
disease (MRD) is the lowest level of leukemic cells detectable with a certain diagnostic 
procedure. The method should achieve if possible a sensitivity level of 10
-4
 – 10
-5
, that means 
to detect one malignant cell among 10000 or 100000 cells. Analysis of MRD is important not 
only because it defines therapy in an increasing number of protocols but it also predicts 
outcome independently of other prognostic factors. The AIEOP-BMF ALL 2000 study 
involves real-time quantitative PCR (RQ-PCR) analysis of clone-specific gene 
rearrangements while the BIOMED-1 study includes additionally the flow cytometric 
immunophenotyping and when there is a certain chromosome translocation the analysis of 
breakpoint fusion region related chimera mRNA expression by real-time quantitative reverse 
transcriptase PCR (RQ-RT-PCR) to monitor MRD.  
 Among various cell based approaches, flow cytometric (FCM) immunophenotyping is 
a rapid, simple and sensitive method for MRD analysis. It relies on the expression of 
uncommon or aberrant phenotypes of leukemic cells, which are present in many but by far not 
all cases of pALL. The immunophenotype used to differentiate leukemic cells should not 
coincide with any normal lymphoid cells, taking into account that certain immunophenotypes 
apparently not present in bone marrow cells of healthy individuals, may become visible in 
actively proliferating bone marrow of leukemia patients after chemotherapy. Another 
important factor affecting the reliability of FCM is the number of cells available to perform 
the measurement. If we want to detect 1 leukemic cell among 10000 normal ones, at least 
100000 mononuclear cells should be examined, since at least 10 leukemic hits should be 
present to reliably interpret the results of FCM. The markers used should be expressed stably 
on leukemic cells, at the same time the investigator should be aware of that gain or loss of 
certain markers may occur during chemotherapy. Further limitation of this method is that 
4 
 
immunophenotypic shifts may occur during the course of the disease, so preferably at least 
three or more different leukemia-specific markers should be monitored per patient to prevent 
false negative results.  
Another promising, – however, for MRD analysis not widely used – cell based method 
is scanning fluorescent microscopy (SFM). The method is briefly, on cells selected based on 
specific phenotype – after in situ labeling and relocalization – investigation of genotype can 
be performed, thus, virtually the pheno- and genotype of the same object can be investigated. 
By predefined search criteria, large number of cells can be scanned automatically. First, single 
and overlapping cells must be separated on the basis of morphometric parameters of nuclei 
then the autofluorescent objects should be excluded. It is followed by immunophenotyping, 
thus the subsequent fluorescent in situ hybridization (FISH) analysis is carried out on single, 
not autofluorescent, marker-of-interest positive cells. Through automated scanning of 
immunofluorescence and FISH signal pattern 10
4
 cells can easily be examined without 
significant hands-on time. Since SFM is an in situ cell-based technique suitable for testing 
both phenotype and genotype, this method was used for MRD detection instead of  
flow cytometry. 
 PCR analysis of antigen receptor gene rearrangements used for MRD monitoring is a 
reliable, accurate method and available in most cases of childhood ALL. Rearranged 
immunoglobulin (IG) and T-cell receptor (TCR) genes are present in a single copy per cell, 
thus using real-time PCR technique allows a very precise determination of MRD. The  
B-cell ALL (B-ALL) carries IG heavy chain (IGH) in more than 90%, TCR-δ (TCRD) in  
ca. 80%, TCR-γ and IG light chain – kappa deleting element (IGK-Kde) in ca. 50%, TCR-α 
and TCR-β gene rearrangements in 46% and in 29%, respectively. However, IG and TCR 
genes might undergo secondary rearrangements leading to oligoclonality, i.e. subclones 
carrying different clonal IG/TCR gene rearrangements may occur. It is possible that some 
minor clones are hidden at the time of diagnosis and become detectable and dominant only at 
a later phase of the disease. Therefore the examination of two or more different 
rearrangements is recommended. Although in the majority of leukemic patients it is possible 
to identify more than one marker, in about 30% of cases all of them are not detectable with 
sufficient sensitivity. Identifying the clone specific region of two or more markers per patient 
is a relatively costly and time-consuming process. 
 Leukemic cells can also be distinguished from normal cells in the presence of a 
specific translocation as the fusion gene could result in the expression of aberrant mRNA.  
In addition to the high sensitivity of the method further advantage is the close relationship 
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between the molecular aberration and the leukemic clone, which is independent of cellular 
changes occurring due to therapy or clonal selection. However, chromosomal translocations 
are present only in approximately 30-40% of childhood ALL cases. It is important to know 
that the fusion gene products are only leukemia, and not patient specific, which makes a 
possible cross-contamination and the subsequent false-positive data very difficult to 
recognize. A further disadvantage of the method is that the number of leukemic cells cannot 
be calculated precisely, since the number of transcripts in the leukemic cells can vary from 
patient to patient even in the same ALL subtypes. 
In our research we compared our MRD results measured by cell-based SFM, DNA and 
RNA based PCR methods. The investigations were conducted on the patient subgroup 
carrying the most commonly occurring t(12;21)(p13;q22) (ETV6/RUNX1) chromosomal 
translocation in childhood ALL. While earlier it was reported that the ETV6/RUNX1 
translocation positive cases have a favorable outcome, other studies contested this because of 
the high incidence rate of late relapses. The question arose whether with the cell, DNA and 
RNA based techniques, i.e. with methods detecting different biological targets, there is any 
heterogeneity detectable in this group of patients which could explain the discrepancies in the 
literature. 
 
2. Aims 
 
1. Identification of t(12;21) positive pALL cases among the bone marrow samples sent to 
the Department of Pathology, University of Pécs, using RT-PCR.  
2. Identification of the clonal gene rearrangements and design of clone specific primers for 
the t(12;21) positive cases. 
3. Investigation of the minimal residual disease on the follow-up samples of these patients 
using 
a. RNA-based RQ-RT-PCR method, 
b. DNA-based RQ-PCR method, 
c. cell-based SFM method. 
4. Description of practical difficulties of each step of the procedure illustrated by 
representative examples.  
5. Comparison of the RNA and DNA based MRD results measured by real-time PCR, 
exploring the causes of possible discrepancies.  
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6. Comparison of the RNA and DNA based MRD data measured by real-time PCR with 
the results of cell-based, combined pheno- and genotype examining scanning 
fluorescent microscopy, exploring the causes of possible differences.  
7. Analysis of a patient with multiple subclones.  
 
3. Materials and methods 
 
3.1. Samples 
 Investigations were conducted on bone marrow samples of pediatric acute 
lymphoblastic leukemia patients diagnosed in the Pathology Department of the University of 
Pécs. Our lab received samples from the Department of Pediatrics University of Pécs, 
Department of Pediatrics University of Szeged, Teaching Hospital Markusovszky 
Szombathely, and the Borsod-Abaúj-Zemplén County Hospital and University Hospital 
Velkey László Pediatric Health Care Centre. The diagnosis of leukemia was based on the 
WHO 2008 diagnostic criteria. In case of a precursor B-ALL, the t(12;21) translocation was 
screened and patients positive for this rearrangement were further investigated. Beyond the 
diagnostic bone marrow aspiratum follow-up samples defined by therapeutic protocol arrived 
on day15 (d15), after the induction period on day33 (d33), at the beginning of Protocol 
M/consolidation phase, before the delayed re-intensification in month5 (m5) and after the end 
of the treatment (0.5 year intensive + 1.5 year maintenance therapy). In case of relapse the 
procedure started from the beginning. All children were treated according to 
ALL IC-BFM 2002 protocol. Written informed consent was obtained from the children’s 
parents or guardians and the study was conducted according to the Declaration of Helsinki. 
 
3.2. DNA and RNA extraction 
 Bone marrow mononuclear cells (MNC) were separated by density centrifugation. 
5x10
5
 cells were used for cytospin preparations. DNA was isolated from fresh or frozen  
1x10
7
 MNCs with QIAamp
®
 DNA Blood Mini Kit according to the manufacturer’s protocol. 
Total RNA was isolated directly from 2x10
7
 MNCs with TRIzol
®
 reagent according to the 
vendor’s recommendation.  
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3.3. t(12;21) RT-PCR 
 Reverse transcription and nested PCR was performed using primers and protocols 
described in the literature. REH cell line harbouring the t(12;21)(p13;q22) was used as 
positive and K562 as negative control. PCR products were evaluated for clonality by 
2% agarose gel electrophoresis. 
 
3.4. t(12;21) RQ-RT-PCR 
 1 µg RNA of the t(12;21) positive patients was reverse transcribed using 1st Strand 
cDNA Synthesis Kit for RT-PCR (AMV). cDNA was subsequently amplified in 
LightCycler
TM
 rapid thermal cycler system. The ETV6/RUNX1 fusion transcript was detected 
by using fluorescent hybridization probes. The PCR was accomplished with LightCycler 
FastStart DNA Master Hybridization Probes according to the manufacturer’s protocol. After 
initial denaturation, a total of 50 cycles of denaturation, annealing and extension were 
performed, completed with melting curve analysis and cooling. The RNA level was 
normalized by the level of the human glucose-6-phosphate dehydrogenase (G6PDH) RNA 
present in the same cDNA using LightCycler-h-G6PDH Housekeeping Gene Set. 
 
3.5. IGH, IGK-Kde and TCRD PCR 
 Monoclonal IG heavy chain (IGH), IG light chain – kappa deleting element (IGK-
Kde) and T-cell receptor-δ (TCRD) gene rearrangements were identified with PCR and 
heteroduplex analysis using family specific primers. A mixture of periferial blood MNCs 
from five healthy donors was used as negative, and the REH cell line as positive control, 
respectively. After initial denaturation, a total of 40 cycles of denaturation, annealing and 
extension were performed, completed with a final elongation and heteroduplex analysis. The 
PCR product was size fractionated on polyacrylamide gel electrophoresis and visualized with 
0.5 μg/ml ethidium-bromide. In case of clonal gene rearrangements the DNA product was 
regained from the polyacrilamide gel using GenElute
TM
 Gel Extraction Kit. Fluorescent 
sequencing was performed with BigDye
®
 Terminator Cycle Sequencing Kit and  
ABI automated sequencer according to the instructions of the manufacturer. The sequencing 
was performed in both the forward and the reverse direction to avoid accidental sequencer 
reading failure.  
 The immunoglobulin and the TCR genes that belong to the immunoglobulin 
superfamily genes develop after the so-called V(D)J-recombination which combines one of 
each germline variable (V), diversity (D) and joining (J) gene segments. During the  
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V(D)J-recombination the terminal deoxynucleotidyl transferase enzyme adds non-templated 
nucleotides (N) to the joining D-J, and V-DJ DNA segments, furthermore, addition of 
germline encoded specific palindromic nucleotides (P) may occur. A clone specific primer 
can be designed to the unique junctional region of the monoclonal and identical gene 
rearrangements of the leukemic cells. To identify the clone specific junctional regions the 
germline V, D, J genes were found using the BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
and IMGT (www.imgt.org) online sequence alignment tools. Clone specific primers covering 
the junctional regions were designed using the Oligo 6 Primer Analysis Software. 
 
3.6. IGH, IGK-Kde and TCRD RQ-PCR 
 RQ-PCRs were performed with LightCycler
TM
 rapid thermal cycler system with 
germline reverse primers and probes described in the literature and the forward junctional 
region specific primers designed by ourselves. The product was detected by fluorescence 
using TaqMan probes. FAM was chosen as reporter dye at the 5’-end of the probes and 
TAMRA as the quencher dye at the 3’-end. Normal MNC DNA and sterile water were used as 
negative controls. After initial denaturation, a total of 50 cycles of denaturation, annealing and 
extension were performed completed with cooling. Sensitivity was established by making 
serial 10-fold dilutions of diagnostic DNA into negative control MNC DNA. Sensitivity was 
defined by the largest, but still detectable dilution. Albumin gene was used to correct quantity 
and quality. Standard curve was created using 10 fold dilution series from Human Genom 
Albumin. 
 
3.7. Immunocytochemical preparation 
 SFM investigations were conducted on cytospin preparations made from 5x10
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aliquots of mononuclear cells. Unconjugated mouse anti-CD10 was used as primer antibody, 
the reaction was developed by biotin-labeled anti-mouse antibody and avidin-FITC. The 
slides were covered with 0.005 g/ml Vectashield-DAPI solution. 
 
3.8. Scanning fluorescent microscopy (SFM) 
The system used for automated scanning and analysis of slides was composed of a 
motorized microscope station (Zeiss Axioplan 2ie MOT) with high-resolution monochrome 
CCD camera. The Metafer 4.0 software was used for digital capturing, processing and 
cytometric measurements. The microscope was equipped with 100W HBO lamp, DAPI, 
FITC, SpectrumGreen and SpectrumOrange filters, as well as Zeiss Fluar 10x/0.5 and  
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Plan-Neofluar 40x/0.75 objectives. For identification of nuclei and CD10 
immunofluorescence detection, 10x objectives and the MetaCyte software module were used.  
After autofocusing in DAPI counterstain channel, close-fitting, non-overlapping 
digital images were captured of the total area of cytospin preparations. X and Y coordinates of 
all objects (suspected cells) were stored for later relocalization. Next, pixel-based mean  
FITC-CD10 signal intensities were measured within each identified object using fixed 
integration time (0.58 sec). The pixel intensity was also measured in a control channel 
(SpectrumOrange) in order to identify and exclude autofluorescent objects. DAPI, FITC and 
SpectrumOrange images of cell like objects were stored and displayed in a gallery in 
combined RGB (red-green-blue) format, along with distribution of pixel intensities for both 
FITC and SpectrumOrange. This allowed the separation of CD10+ cells from CD10- cells and 
autofluorescent objects, respectively. ETV6/RUNX1 iFISH signals were evaluated only in 
single, non-autofluorescent, CD10+ cells.  
 
3.9. Interphase fluorescent in situ hybridization (iFISH) 
 After immunophenotyping, interphase fluorescence in situ hybridization (iFISH) was 
performed on the same sample. Cells were stripped and nuclei were labeled with Vysis LSI 
ETV6/RUNX1 dual-color, rearrangement-specific fusion, and extrasignal probe set according 
to the manufacturer's instructions. 
 Relocalization of CD10+ cells was based on the previously stored X and Y 
coordinates and gallery images, using the Metafer 4.0 software. The relocalized nuclei were 
captured both in SpectrumGreen and SpectrumOrange signal channels using the Isis (In situ 
imaging system) module. Subsequently, FISH pattern of CD10+ cells was investigated and 
interpreted. Translocation negative nuclei contained two red and two green signals, whereas 
in the translocation positive nuclei a fusion (yellow) and an extra signal (red) occurred beside 
the one green and one red signal representing the alleles not involved in the rearrangement. 
On average 27050 cells were analyzed per cytospin preparation. Sensitivity and 
specificity of the combined immunofluorescence and iFISH method were 98.67% and 
99.97%, respectively. To consider a cell population as truly positive, double criteria had to be 
met: both the CD10+ and the t(12;21)+ cells had to exceed the mean false positivity + 2 S.D. 
threshold of immunophenotyping (0.21% + 2 x 0.15% = 0.51%) and genotyping by FISH 
(15.80% + 2 x 0.75% = 17.30%), respectively. 
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4. Results 
 
4.1. Samples 
According to the RT-PCR investigations we identified 14 ETV6/RUNX1 translocation 
positive precursor-B-ALL children and the cell, DNA and RNA-based tests were conducted 
on their follow-up samples. The mean age at diagnosis ranged from 2 to 17 years with an 
average of 6.07 years, the sex ratio was 1:1. The average follow-up period was 30.5 months 
(20-38 months). One patient relapsed after 24 months, and another one developed only 
localized meningeal relapse after 27 months from the onset of the disease. 
Diagnostic samples collected before the start of the therapy contained very large 
number of mononuclear cells, while the MNC number count significantly decreased due to 
the effect of therapy in follow-up samples. The volume of the submitted materials was also 
highly variable, which was attributable to the difficulties of bone marrow aspiration. It also 
occurred that the total number of cells was not sufficient to perform all three tests, in which 
case we had to set up an order of priority. We considered that optimally for RNA isolation 
2x10
7
, for DNA isolation 1x10
7
, but for making citospin preparation far less than these, only 
5x10
5
 cells were required. However, the sensitivity of SFM is lower than the sensitivity of the 
other two methods. Taking all these considerations into account we always made in such a 
situation an individual decision.  
The ratio of the amount of a specific target measured using a particular method at the 
follow-up time point and that in the untreated sample of the same patient defined the 
MRD level (this value at diagnosis was 1.0) which was also expressed as tumor dilution 
(clearance). This allowed comparison of data obtained by the different methods. The tumor 
dilution values were defined as the negative logarithm of the relative amount of specific 
target.  
 
4.2. Comparison of the RQ-PCR and RQ-RT-PCR data 
 We were able to detect clonal rearrangements in all patients by DNA based RQ-PCR 
procedure. In 6 cases one, in 7 cases two, and in one case three clonal markers could be 
identified. If RQ-PCR analysis of the same sample with two or more independent 
DNA markers resulted in different MRD levels, the highest MRD value has been taken into 
account.  
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The relative amount of ETV6-RUNX1 mRNA expression at diagnosis showed a high 
degree of variability, the average value was 4.59 (range: 0.51–12.77). During comparison of 
the tumor clearance detected by two different methods, in an individual case discordant result 
was defined as at least one order of magnitude difference. Two out of 6 cases showed this 
discrepancy at d15. In both cases RQ-RT-PCR results indicated greater reduction of leukemia 
and in one of these cases the differences persisted up to the next time-point, too. At d33 
differences in 3 out of 12 cases have been noticed; in every case the expression based MRD 
was lower. In two of these cases the difference remained also at w12. At m5 the differences 
have been identified in 3 out of 14 cases and again the expression based values referred to 
higher tumor dilution. Thus, out of 42 comparisons in 10 cases (24%) the clearance of a 
specific target exhibited difference of at least one order of magnitude always in favor of the 
RNA data indicating higher dilution, thus lower MRD level. 
 
4.3. Comparison of RQ-PCR, RQ-RT-PCR and SFM data 
 The percentage of CD10 and FISH positive blasts among the mononuclear bone 
marrow cells is proved to be on average 82.88% at onset of therapy. Due to the false positive 
rate (3x10
-4
) and the chosen cut-off value (mean+2 S.D. = 9 x 10
-4
) for positivity threshold of 
the SFM method, the DNA, RNA and cell based results were compared at 10
-2
 and 10
-3
 MRD 
cut-off levels. By 10
-2
 MRD threshold all patients proved to be negative by all three methods 
at d33, whereas at 10
-3
 MRD level this was true only for the RNA based approach. At this 
level and using DNA based analysis all patient reached negativity only by w12. In contrast to 
the RNA and DNA analysis which indicated MRD negativity at 10
-3
 level for all patients by 
d33 and w12, respectively, a fraction of patients with residual disease higher than 10
-3 
never 
dropped to zero by cell based SFM analysis. In addition, by this approach and at this MRD 
level, the ratio of patients with MRD increased from w12 to m5 significantly (from 13% to 
36%), whereas this value remained zero by both RNA and DNA analyses.  
This larger fraction of 10
-3
 MRD positive patients by SFM at m5 exhibited on average 
smaller tumor dilution factor (1.9, range: 1.4 – 2.5) as compared to that (2.1) at w12. Among 
patients with detectable disease by SFM at m5 two had 1.5 log, the others 2.6 – 3.1 log higher 
residuum when compared with DNA data, whereas this higher tumor residuum by SFM was 
in the range of 2.9 – 4.2 order of magnitude as compared with RNA based data. In summary, 
1.5 – 4.2 log difference between the amounts of DNA–RNA as well as SFM targets was 
detected in 5 out 14 patients at m5. 
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If residual leukemic cells had been detected with SFM method, they should have been 
detected with RNA and DNA-based methods too, because of the higher sensitivity of  
PCR-based techniques. However, a preleukemic cell carrying the translocation, but still 
containing germline antigen receptor gene and not expressing RNA, cannot be detected with 
PCR-based techniques but with SFM. Based on the FISH signal pattern we have interphase 
cytogenetic evidence, that the CD10-iFISH positive cells detected by SFM in the 5 patients at 
w12 and m5 were really precursor leukemic cells and not residual tumor cells. To the 
development of t(12;21)+ pALL besides the in utero monoallelic rearrangement secondary 
post-natal aberrations are also necessary. This is in 75% of the cases the deletion of the 
normal ETV6 gene, resulting in loss of heterozygosity (LOH) or the duplication of the fusion 
gene. In the untreated samples of the 5 patients complex cytogenetic deviations were showed: 
in 3 cases rearrangement and normal ETV6 deletion, in 1 case double fusion gene and in 
1 case subclones carrying alternately the two previous variants were identified. In contrast, in 
the post d33 follow-up samples of these patients in the CD10+ cells only one fusion and 
normal ETV6 and RUNX1 alleles were present, which does not refer to leukemic but leukemia 
precursor cells.  
 
4.4. Analysis of a patient with multiple subclones 
 Clone specific DNA based RQ-PCR analyses allowed us to identify a patient with 
potentially more than one leukemia subclone. In fact, using the multiplex IGH PCR, in 1 out 
of the 14 patients three clonal IGH gene rearrangements using three different VH family genes 
were detected. Sequencing data confirmed this and identified the germline genes as VH3-30, 
DH6-13, JH4 (IGH1); VH4-31, DH6-13, JH4 (IGH2); VH1-3 DH3-9, JH6 (IGH3). Two out 
of these three subclones could be justifiably suspected also by flow cytometric phenotyping 
according to the unique CD10 and CD34 expression of the leukemic cells. During 
investigation of tumor cell clearance by clone specific DNA based RQ-PCR method, different 
responses due to the different subclones were observed. Although all three subclones became 
undetectable by w12 and remained there by m5, different tumor dilution hallmarked by up to 
1.4 log difference among the three subclones could be detected at d33. This significant 
difference among the one and the other two leukemia subclones of this patient might also be 
existed at later checkpoints (w12 and m5), too, but it was not seen due to the low amount of 
targets that outranged the sensitivity of our RQ-PCR method. 
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5. Discussion 
 
Childhood acute lymphoblastic leukemia is treated according to recommendations of 
international protocols to which the patients are stratified into standard, medium, and high risk 
groups. The aim of therapy is to further improve the survival, as well as to define risk-based 
treatment taking into account various prognostic factors, e.g. in case of a high-risk patient a 
later relapse can be prevented with more aggressive therapy. Age, diagnostic WBC count, 
early prednisolone response, various structural and numerical chromosomal abnormalities, 
as well as investigation of minimal residual disease are important in determining prognosis. 
The major goal of MRD detection is to identify patients who eventually fall into relapse 
although they belong to good or intermediate prognostic groups, or patients in poor or 
intermediate risk groups, who could benefit from less intensive treatment.  
Currently used strategies for MRD detection rely on the DNA based RQ-PCR analysis 
of clone-specific gene rearrangements, the RNA based RQ-RT-PCR detection of various 
chromosome translocation related chimera mRNA expressions and the cell based flow 
cytometric immunophenotyping. The biological meaning of data obtained by these various 
approaches as well as their different sensitivity level (10
-4
 to 10
-5
, 10
-4
 to 10
-6
 and 10
-3
 to 10
-4
, 
respectively) might render comparison of data and determination of the method of choice 
difficult. Furthermore, each technique has advantages and drawbacks, too. 
An alternative approach to detect rare malignant events among normal cells is 
scanning fluorescent microscopy. Since SFM is an in situ cell-based technique providing both 
phenotype and genotype of the cellular target, this method was used for MRD detection 
instead of flow cytometry. The SFM data were compared with DNA and RNA-based MRD 
values, a comprehensive study which has not been done, yet. 
Our investigations were conducted on t(12;21) translocation positive pALL subgroup 
that makes up appr. 25% of childhood ALL cases. According to the relevant literature there 
are only few reports about the comparison of RQ-PCR and RQ-RT-PCR data monitoring 
MRD in ETV6/RUNX1 positive patients. Discrepancies of more than one or even two orders 
of magnitude between DNA and RNA based MRD levels have been described by some 
authors. 
In our studies we investigated 63 bone marrow samples of 14 ETV6/RUNX1 positive 
patient with DNA and RNA based PCR and in situ cell-based SFM methods. The ratio of the 
amount of a specific target obtained by a particular method at the different follow-up time 
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points and in the untreated sample of the same patient defined the MRD level which was also 
expressed as tumor dilution. This allowed comparison of data obtained by the different 
methods. Having analyzed MRD data we have ended up with three observations: 
 
1. Tumor clearance by chimera mRNA is faster.  
Tumor clearance by chimera mRNA is faster than tumor clearance with other methods 
since in all cases when at least one log difference between MRD of DNA and RNA could be 
detected, the RNA values were always lower. This occurred in significant fraction (appr. in a 
quarter) of analyses. Furthermore, significantly larger fraction of patients reached an MRD 
level of 10
-4
 faster according to RNA-based method than with DNA based technique. These 
findings are not suprising as the RNA results cannot indicate the changes in tumor load under 
all circumstances, but reflect to the number of a particulate chimera mRNA species in sample, 
thus rather to the cellular activity. Chimera expression rate is influenced by local and systemic 
environmental factors, like it may change upon therapy, and even the full chimera gene 
silencing is well documented. These do not contradict to the observations that increase of 
chimera mRNA as detected by RQ-RT-PCR may herald progression (relapse, blastic crisis) of 
a particular disease.  
In summary, we detected faster tumor clearance by the RNA-based method than by 
DNA based technique, thus RQ-PCR monitors much reliably tumor load reduction however, 
RQ-RT-PCR provide valuable information about tumor cell activity. 
 
2. We detected more than 10
-3
 tumor residuum in a couple of patients using SFM. 
The most striking finding is that by the end of the observation period in more than one 
third of patients tumor residuum above 10
-3
 was detected, i.e. CD10 and ETV6/RUNX1 
rearrangement positive cells could be identified by SFM. These values highly exceeded the 
results obtained by DNA or RNA techniques. We do not believe that this is due to technical 
error, as the SFM method for this particular target was carefully adjusted, the results were 
reproducible and the measured values were reliably beyond the false positive rate (0.0003) of 
the combined in situ pheno- and genotyping method. For the same reason we can rule out that 
the normal, reactive CD10+ hematogones, that are known to increase significantly in number 
in the post-chemotherapy period, was identified by SFM. The large differences between SFM 
and RNA results can be explained by what have been discussed under the first section of this 
chapter. However, as both the clonal DNA markers as well as the immunofluorescence/FISH 
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combined method identify tumor residuum on a cell-by-cell basis, the significant difference 
between DNA and SFM data need further considerations.  
According to the literature, retrospective analysis of the umbilical cord blood samples 
of children who subsequently developed ETV6/RUNX1 + pALL, the t(12;21) translocation on 
one allele was identifiable already at birth in a large fraction (77%) of the examined patients. 
These cells reside in the lymphoid stem cell and pro-B-cell compartment, have germline IG 
genes and the fusion gene might be silenced similarly to early Ph+ progenitors. Leukemia 
arises when loss of heterozygosity (LOH) occurs in that region, which is typically detected at 
the onset of this disease.  
We believe that we have detected mainly at m5 by SFM these ancestor, preleukemic 
cells (and not the original tumor cells) which due to the aforementioned reasons could not be 
picked up either by RQ-PCR or RQ-RT-PCR. Based on the FISH signal pattern we have 
interphase cytogenetic evidence, that the with SFM method detected double CD10-iFISH 
positive cells at the 5 patient at w12 and m5 are really precursor leukemic cells and not 
residual tumor cells. The untreated samples of the 5 patients showed complex cytogenetic 
deviation, beside the t(12;21) translocation, deletion of the normal ETV6, double fusion gene 
and combination of these was detectable. In contrast, in the post d33 follow-up samples of 
these patients in the CD10+ cells only one fusion and normal ETV6 and RUNX1 alleles were 
present, which does not refer to leukemic but leukemia precursor cells.  
In addition to the cord blood study, further evidence for the existance of such 
preleukemic clones is provided by publications presenting that the relapsed ETV6/RUNX1+ 
pALL still harbored the original t(12;21)(p13;q22) breakpoint fusion, but exhibited a fully 
different phenotype, antigen receptor gene rearrangements and/or karyotype. These ancestor, 
preleukemic cells might be the source of a relapse which typically occurs late in this group of 
pALL, likely, as it does not develop from a true residuum.  
One of our patients who relapsed 24 months after the onset, is among the 5 patients for 
who we could detect these CD10 and ETV6/RUNX1+ supposedly ancestor cells by SFM. On 
the contrary, the other patient who exhibited meningeal, but not bone marrow relapse, 
developed very likely from local residuum, did not belong to that 5 patients’ category. These 
data might strengthen the significance of the SFM findings.  
In summary, only the combined in situ immuno- and genotyping analysis completed 
by SFM was able to detect the CD10 and t(12;21) positive, but antigen receptor gene 
rearrangement negative cells. We could identify these cells which are likely ancestor 
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preleukemic cells in 1/3 of the patients in the post-induction period. These cells might be the 
source of some late relapses in this group of disorder. 
 
3. Detection of leukemic subclones with different biological behavior in one patient.  
In one of our patients we could identify multiple leukemia subclones according to the 
IGH gene variable region analysis. Sequencing of the full V-J regions confirmed the presence 
of three distinct subclones. None of them has been smoldering background subclone as all 
three were present in similarly high quantity at the onset of the disease. Two of them behaved 
similarly and exhibited a significantly smaller tumor clearance than the third one during the 
induction period. This finding reveals clonal heterogeneity in response to the same therapy. 
In summary, different subclones identified with DNA-based method may respond 
distinctly to treatment, therefore the relationship between the antigen receptor gene 
rearrangements and response to therapy needs further investigation. 
 
6. Summary of new findings 
 
1. For minimal residual disease (MRD) detection in ETV6/RUNX1 positive childhood 
pre-B ALL in addition to the RNA-based RQ-RT-PCR and DNA-based RQ-PCR we 
developed a combined immunophenotype-iFISH scanning fluorescence microscopy (SFM) 
method based on consecutive labeling and detection of CD10 (immunofluorescence) and 
t(12;21) translocation (iFISH). The CD10+/t(12;21)- hematogones can be distinguished from 
CD10+/t(12;21)+ leukemic cells at 9x10
-4
 level, so the leukemic cells can be identified with 
100% certainty even below the 10
-3
 level.  
 
2. We are the first who compared minimal residual disease data obtained by DNA and 
RNA-based real-time PCR techniques with the cell-based scanning fluorescence microscopy 
results.  
 
3. From d33 of treatment detected MRD level was lower than 10
-3
 measured by 
quantitative RNA and DNA PCR, as well as with combined and immunophenotyping-iFISH 
method in follow-up bone marrow samples of ETV6/RUNX1+ pre-B pALL patients. 
However, from d33 in 36% of patients 10
-3
 – 10
-2
 CD10+/t(12;21)+ cells were detectable with 
SFM. These cells showed monoallelic aberrations, were not detectable with the much more 
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sensitive RNA based RQ-RT-PCR and clone specific DNA-based RQ-PCR techniques, so 
they were not residual leukemic cells but leukemia precursor bone marrow cells.  
 
4. We detected and visualized for the first time in treated t(12;21)+ pre-B pALL 
patients in utero originated leukemia precursor cells, detectable only with the newly 
developed combined immunophenotype-iFISH method. The presence of such precursor cells 
may relate to relapses, so investigation of them could be predictive for the course of the 
disease. 
 
5. In one patient we could identify multiple leukemia subclones according to the IGH 
gene variable region analysis. Our research revealed different clearence and sensitivity of the 
subclones to chemotherapy. Antigen receptor gene rearrangements and the response to 
therapy need further investigation in the future.  
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